Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
about
Gut Microbiota and Metabolic Health: The Potential Beneficial Effects of a Medium Chain Triglyceride Diet in Obese IndividualsMetabolic aspects of adult patients with nonalcoholic fatty liver diseaseGalectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitisPediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directionsAmeliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats.Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation.Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease.Hepatocyte mitochondrial DNA released in microparticles and toll-like receptor 9 activation: A link between lipotoxicity and inflammation during nonalcoholic steatohepatitis.Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH.Efficient scalable production of therapeutic microvesicles derived from human mesenchymal stem cells.Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.Apoptosis and non-alcoholic fatty liver diseases.Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH
P2860
Q26748972-D383208B-8E7A-4B24-A077-B2FCF11EB4A4Q28067490-52131856-BEE6-466A-A393-4B1DDE581766Q28069174-11021C79-9604-470B-84FF-9EF80F34012EQ28079432-FEB4ECE6-89E0-4610-84A0-161165AC88E9Q37595268-ED914A5B-D69E-42D1-A7FF-9B8015B44841Q40959440-5CA4EA51-1F65-477D-8DD6-3A1EB5FA2020Q41185516-5C036BC1-2C55-4BF0-92DF-EF5F3011C841Q42408750-F1334537-C577-4F03-9EBF-50B95A849683Q46270590-BD06C558-C8D2-4285-A276-CBFD9639D538Q47722619-EDFB010F-4E64-4D04-A866-6CC28CEE1B02Q47768810-9F5941E5-DC49-410F-AC8A-318888739E5EQ55503094-7442AC60-D0F1-47D9-853F-E9C89DE24B48Q57210121-9B31F65B-00F5-4093-95FD-66A033618F56
P2860
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@ast
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@en
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@nl
type
label
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@ast
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@en
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@nl
prefLabel
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@ast
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@en
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@nl
P2860
P3181
P356
P1476
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
@en
P2093
Davide Povero
P2860
P3181
P356
10.4093/DMJ.2016.40.1.1
P407
P577
2016-02-01T00:00:00Z